Skip to main content

Apogee Therapeutics, Inc.

APGEDelisted Sep 3, 2026
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001974640

Apogee Therapeutics, Inc. was delisted on Sep 3, 2026; its insiders filed their last Form 4 on Sep 3, 2026; 288 institutions reported holding it in 13F filings for Q2 2026, worth $8.93B in total; Soros Fund Management was the only superinvestor holding it.

Q1 2025 vs. Q4 2024

How the institutions holding Apogee Therapeutics, Inc. changed between Q4 2024 and Q1 2025.

All holders in Q1 2025All holders in Q4 2024

13F holders of APGE: Q4 2024 compared with Q1 2025
MeasureQ4 2024Of which not filed for Q1 2025Q1 2025Change
Holders1582169+13
Shares57.9M143.5K61.5M+3.76M (+6.5%)
Value$2.62B$6.50M$2.30B−$313.4M (−12.0%)

2 institutions that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so the changes leave them out.

New holders (34)

Institutions that held Apogee Therapeutics, Inc. at the end of Q1 2025 but not at the end of Q4 2024.

Sold out (21)

Institutions that held Apogee Therapeutics, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.

Not filed for Q1 2025 yet (2)

Institutions that held Apogee Therapeutics, Inc. at the end of Q4 2024 and haven't filed a 13F for Q1 2025. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding APGE in Q4 2024 that haven't filed for Q1 2025
InstitutionShares, Q4 2024Value, Q4 2024
Nuveen Asset Management, LLC137,826$6.24M
AlphaCentric Advisors LLC5,649$255.9K